In case anyone missed this presentation.
https://www.aats.org/resources/lb4-prospective-single-center-randomized-control-trial-to-evaluate-the-safety-and-feasibility-of-a-novel-allogenic-mesenchymal-precursor-cell-therapy-in-patients-with-hypoplastic-left-heart-syndrome-2
Doctors are impatient for this stem cell therapy for their patients… not my words but
rather the words from a doctor during question time.
Well done to Boston’s Children’s Hospital for trailblazing this new treatment… again a doctor’s words, not mine.
Bring on MSB’s Phase 3 trial
Ann: FDA Grants Rare Pediatric Disease Designation for Revascor, page-223
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.55 |
Change
0.020(0.79%) |
Mkt cap ! $2.924B | |||
| Open | High | Low | Value | Volume |
| $2.62 | $2.70 | $2.55 | $19.63M | 7.505M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 32100 | $2.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.56 | 40000 | 2 |
View Market Depth
| Last trade - 14.10pm 26/12/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
